|| List of recent Peptide-related patents
|Carrier for separation, method for separation of compound, and method for synthesis of peptide using the carrier|
Disclosed are a carrier for use for separation purpose and a method for separation of a compound which enable a chemical reaction to be performed in a liquid phase, enable a compound of interest to be separated from the liquid phase after the completion of the reaction readily, enable the separated compound to be evaluated by structural analysis or the like while the compound being bound to the carrier, and enable the compound to be separated from the carrier readily. A carrier for separation which has a reaction site capable of reacting with other compound on a benzene ring, and a long-chain group having a specified carbon atom(s) at each of the ortho-position and the para-position of the reaction site through an oxygen atom..
|Therapeutic methods for type i diabetes|
The invention relates to the treatment and prevention of type i diabetes. More specifically, the invention relates to compounds that treat or prevent the body's immune system from destroying β-cells (i.e., insulin-producing cells in the pancreatic islets of langerhans) by inhibition of jnk2, selective inhibition of jnk2, or inhibition of the expression of the mapk9 gene or gene product.
|New conjugated molecules comprising a peptide derived from the cd4 receptor coupled to a polyanionic polypeptide for the treatment of aids|
This invention relates to a conjugated molecule comprising a peptide derived from the cd4 receptor coupled to an organic molecule by means of a linker as well as a process for its preparation. Said organic molecule comprises a 5 to 21 amino acid anionic polypeptide.
|Kdr and vegf/kdr binding peptides and their use in diagnosis and therapy|
The present invention provides polypeptides, peptide dimer, and multimeric complexes comprising at least one binding moiety for kdr or vegf/kdr complex, which have a variety of uses wherever treating, detecting, isolating or localizing angiogenesis is advantageous. Particularly disclosed are synthetic, isolated polypeptides capable of binding kdr or vegf/kdr complex with high affinity (e.g., having a kd<1 μm), and dimer and multimeric constructs comprising these polypeptides..
|Polycomb repressive complex 2 (prc2) inhibitors and uses thereof|
The present invention relates to polycomb repressive complex 2 (prc2) peptide inhibitors and their use for the treatment of cancer and other conditions associated with aberrant prc2 methyltransferase activity.. .
|Method for administering omega-conopeptide|
The present invention is directed to a method of producing analgesia in a mammalian subject. The method includes administering to the subject an omega conopeptide, preferably ziconotide, in combination with an analgesic selected from the group consisting of morphine, bupivacaine, clonidine, hydromorphone, baclofen, fentanyl 1, buprenorphine, and sufentanil, or its pharmaceutically acceptable salts thereof, wherein the ω-conopeptide retains its potency and is physically and chemically compatible with the analgesic compound.
|Soluble hybrid fcgamma receptors and related methods|
Disclosed are soluble hybrid fcγ receptor (fcγr) polypeptide compositions and related methods of using such polypeptides to treat igg-mediated and immune complex-mediated inflammation. Also disclosed are related compositions and methods for producing the soluble hybrid fcγr polypeptides..
|Methods for prevention and treatment of acute renal injury|
The disclosure relates to a method for protecting a kidney from renal injury. For example, acute renal injury may be associated with decreased or blocked blood flow in the subject's kidney or exposure to a nephrotoxic agent, such as a radiocontrast dye.
|Polypeptide compounds for inhibiting angiogenesis and tumor growth|
In certain embodiments, this present invention provides polypeptide compositions, including compositions containing a modified polypeptide, and methods for inhibiting ephrin b2 or ephb4 activity. In other embodiments, the present invention provides methods and compositions for treating cancer or for treating angiogenesis-associated diseases..
|Glucagon antagonist-gip agonist conjugates and compositions for the treatment of metabolic disorders and obesity|
Provided herein are peptide combinations comprising a gip agonist peptide and a glucagon antagonist peptide. In some embodiments, the peptide combination is provided as a composition, e.g., a pharmaceutical composition, while in other embodiments, the peptide combination is provided as a kit.
|Engineered polypeptides having enhanced duration of action|
Compounds are provided having inter alia good duration of action, high potency and/or convenient dosing regimens including oral administration. The compounds are engineered polypeptides which incorporate an albumin binding domain in combination with one or more biologically active polypeptides.
|Anticancer and anti-obesity cyclic peptide agents|
For use in anticancer or anti-obesity.. .
|Pharamaceutical composition for preventing or treating human immunodeficiency virus|
There is provided a pharmaceutical composition for preventing or treating human immunodeficiency virus, and more particularly, to a pharmaceutical composition and health functional food for preventing or treating/improving human immunodeficiency virus, the pharmaceutical composition and health functional food including a new compound with chitooligosaccharides conjugated amino acids or dipeptides as an effective component. The new compound has an excellent anti-hiv effect through an activity of inhibiting a hiv initial infection by interrupting an interaction between host-virus membranes, and also activities of inhibiting reverse transcriptase and protease of hiv.
|Methods and systems for adenovirus interaction with desmoglein 2 (dsg2)|
The present invention provides compositions, compounds, and methods relating to recombinant adenoviral-based polypeptides for treating disorders associated with epithelial tissues.. .
|Plasmids and methods for peptide display and affinity-selection on virus-like particles of rna bacteriophages|
The present invention relates to a system and method for controlling peptide display valency on virus-like particles (vlps), especially including ms2 or pp7 vlps. In this method, large amounts of wild-type and low quantities of single-chain dimer coat proteins may be produced from a single rna.
|Dgat genes and methods of use for triglyceride production in recombinant microorganisms|
The present invention provides novel diacylglycerol acyltransferase (dgat) genes, including novel genes encoding localization peptides. The present invention also provides recombinant cells, such as algae, transformed with dgat genes and methods of using such recombinant cells to produce triglyceride..
|Polypeptides having xylanase activity and polynucleotides encoding same|
The present invention relates to isolated polypeptides having xylanase activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides..
|Glycosyl hydrolase enzymes and uses thereof for biomass hydrolysis|
The present invention relates to compositions that can be used in hydrolyzing biomass such as compositions comprising a polypeptide having glycosyl hydrolase (gh) family 61/endoglucanase activity and/or a β-glucosidase polypeptide, methods for hydrolyzing biomass material, and methods for using such compositions.. .
|Mammalian cell culture processes for protein production|
The present invention describes methods and processes for the production of proteins by animal cell or mammalian cell culture. In one aspect, the methods comprise the growth of cells in a growth factor/protein/peptide free medium.
|Protein production in microorganisms of the phylum labyrinthulomycota|
The present invention relates to recombinant cells and microorganisms of the phylum labyrinthulomycota and their use in heterologous protein production. Novel promoter, terminator, and signal sequences for efficient production and, optionally, secretion of polypeptides from recombinant host cells and microorganisms are also encompassed by the present invention..
|Selection of host cells expressing protein at high levels|
Described is a dna molecule comprising an open reading frame sequence encoding a selectable marker polypeptide, wherein the dna molecule in the coding strand comprises a translation start sequence for the selectable marker polypeptide having a gtg or ttg start codon, and wherein the orf sequence that encodes the selectable marker protein has been mutated to replace at least half of its cpg dinucleotides as compared to the native orf sequence that encodes the selectable marker protein. Further provided are such dna molecules wherein the orf sequence that encodes a selectable marker polypeptide is part of a multicistronic transcription unit that further comprises an open reading frame sequence encoding a polypeptide of interest.
|Polypeptides having carboxypeptidase activity and polynucleotides encoding same|
The present invention relates to isolated polypeptides having carboxypeptidase activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides..
|Methods for production and purification of polypeptides|
The present invention relates to a method for production and purification of polypeptides. In particular, the present invention relates to a fusion protein comprising a solubility-enhancing peptide tag moiety, a self-aggregating peptide moiety and a moiety of target peptide and to a method for production and purification of target peptides through expressing said fusion protein..
|Electrochemical determination of factor xa inhibitors|
Methods and devices for determining factor xa inhibitors, in particular heparins and fractionated or low-molecular-weight heparins, as well as direct factor xa inhibitors in blood samples. The methods include contacting a blood sample with a detection reagent that contains at least one thrombin substrate having a peptide residue that can be cleaved by thrombin and is amidically bound via the carboxyl end to an electrogenic substance, and with a known amount of factor x reagent and an activator reagent which induces the conversion of factor x into factor xa.
|Method for the diagnosis of rheumatoid arthritis|
The present invention refers to the use of citrullinated synthetic peptides for the diagnosis of rheumatoid arthritis (ra).. .
|Peptide analogues of pa-il and their utility for glycan and glycoconjugate analysis and purification|
Also included are methods for detecting changes in the glycosylation of carbohydrates and for separating biomolecules which contain glycoproteins or glycoconjugates.. .
|Novel genes causing hereditary kidney disease or malformation of the urinary tract|
Isolated nucleotides encoding polypeptides with mutations leading to amino acid substitutions linked to hereditary kidney disease or malformation of the urinary tract are provided herein. Constructs, cells, probes and inhibitory molecules comprising these mutations are also provided and may be used in screening assays for candidate agents to treat or reverse these diseases or alternatively to provide diagnostic tests.
|Biomarkers for in vitro prognosis and diagnosis of graft and trasplant rejection|
Novel peptides, their derivatives and compositions including the same for their use as a tool in prognosis or diagnosis of a grafted organ distress, notably of graft or transplant rejection.. .
|Stabilized bioactive peptides and methods of identification, synthesis, and use|
An intracellular selection system allows screening for peptide bioactivity and stability. Randomized recombinant peptides are screened for bioactivity in a tightly regulated expression system, preferably derived from the wild-type lac operon.
|Infant nutrition with hydrolysed proteins|
The invention concerns a method to treat and/or prevent childhood obesity comprising administering a nutritional composition containing fat, digestible carbohydrates and protein, wherein the protein comprises at least 25 wt. % peptides with a chain length of 2 to 30 amino acids based on dry weight of protein..
|Modified-release microparticles based on amphiphilic copolymer and on active principle(s) and pharmaceutical formulations comprising them|
The present invention relates to novel microparticles formed of amphiphilic polyamino acids which transport active principle(s), ap(s), in particular protein and peptide active principle(s), and to novel modified-release pharmaceutical formulations comprising said ap microparticles. Microparticles of amphiphilic polyamino acid (po) may include at least one ap (associated noncovalently) which spontaneously form a colloidal suspension of nanoparticles in water, at ph 7.0, under isotonic conditions.
|Spherical microcapsules comprising glp-1 peptides, their production and use|
The present invention provides spherical microcapsules comprising at least one surface coating and a core, wherein the at least one surface coating comprises cross-linked polymers, and wherein the core comprises cross-linked polymers and cells capable of expressing and secreting a glp-1 peptide, a fragment or variant thereof or a fusion peptide comprising glp-1 or a fragment or variant thereof. The present applicators is furthermore directed to methods for production of these spherical microcapsules and to the use of these microcapules e.g.
|Adjuvant and antigen particle formulation|
A composition as disclosed is comprised of a plurality of particles and a pharmaceutically acceptable carrier. The particles are comprised of (1) an adjuvant; (2) a biocompatible polymer which maybe a co-polymer such as plga, and (3) a peptide of a sequence of interest, e.g.
|Prodrugs of peptide epoxy ketone protease inhibitors|
This disclosure features compounds that are useful as pro-drugs of epoxy ketone protease inhibitors.. .
|Frizzled-binding agents and uses thereof|
Novel anti-cancer agents, including, but not limited to, antibodies and other polypeptides, that bind to human frizzled receptors are provided. Novel epitopes within the human frizzled receptors which are suitable as targets for anti-cancer agents are also identified.
|Peptide for protection of allergic respiratory disorders|
A peptide (peptide-1) based on the c-terminal of equine cc10 has been discovered that can be used as a vaccine to protect horses from respiratory airway obstruction (rao). Antibodies to peptide-1 may also be administered for short-term passive immunotherapy to rao-affected horses, and can be used to measure the level of cc10 protein in serum to identify potential rao horses (horses with reduced cc10).
|Anthrax and small pox replikins and methods of use|
Isolated peptides of the bacillus anthracis anthrax toxin lethal factor protein px01-107, antibodies specific for the peptides and methods of stimulating the immune response of a subject to produce antibodies to the bacillus anthracis anthrax toxin lethal factor protein px01-107 are disclosed. Also disclosed are isolated peptides of the small pox virus surface antigen s precursor protein, antibodies specific for the peptides and methods of stimulating the immune response of a subject to produce antibodies to the small pox virus surface antigen s precursor protein..
|Apoptosis-inducing molecules and uses therefor|
This invention relates generally to methods and agents for modulating adiposity-related conditions. More particularly, the present invention relates to the use of trail death receptor agonists, including nucleic acids such as trail polynucleotides, peptides and polypeptides including trail polypeptides, trail dr agonist antigen-binding molecules, trail dr peptide agonists as well as small molecule trail dr agonists in compositions and methods for treating or preventing adiposity-related conditions such as obesity, diabetes mellitus and metabolic syndrome..
|Humanized antibodies specific to the protofibrillar form of the beta-amyloid peptide|
The present application relates to humanized antibodies specific to the protofibrillar form of the beta-amyloid peptide, and to the use of said antibodies in the field of alzheimer's disease.. .
|Use of mesenchymal stem cells for the improvement of affective and cognitive function|
Disclosed is the use of mesenchymal stem cells (mscs) and in particular mscs pretreated with pituitary adenylate cyclase-activating polypeptide (pacap) or analogs and fragments of pacap, for treatment of neurodegenerative and psychiatric diseases, and for the improvement of affective and cognitive function in a normal individual or in an individual suffering from a neurodegenerative or neuropsychiatric disease.. .
|Method for treating vascular-related disease|
A method for treating a vascular-related disease in a subject in need thereof, includes administering to the subject a peptide having a sequence xaa-gly-asp. The peptide may have a sequence of seq id nos: 1, 2, 4, 6 to 10.
|Vaccine for treatment and prevention of herpes simplex virus infection|
The present invention relates to methods and compositions for the prevention and treatment of herpes virus infections. The invention provides antigenic peptides, and pharmaceutical compositions comprising complexes of antigenic peptides and adjuvants that can activate an immune response against herpes viruses.
|Molecules specifically binding pancreatic beta cells biomarkers|
The present invention provides a synthetic peptide molecule that specifically binds an fxyd2-gamma isoform of pancreatic beta cells, said synthetic peptide molecule has 25 amino acids.. .